AU658198B2 - Tumour antigen specific antibody, its use and cell in line producing the antibody - Google Patents

Tumour antigen specific antibody, its use and cell in line producing the antibody

Info

Publication number
AU658198B2
AU658198B2 AU19425/92A AU1942592A AU658198B2 AU 658198 B2 AU658198 B2 AU 658198B2 AU 19425/92 A AU19425/92 A AU 19425/92A AU 1942592 A AU1942592 A AU 1942592A AU 658198 B2 AU658198 B2 AU 658198B2
Authority
AU
Australia
Prior art keywords
antibody
cell
antigen specific
tumour antigen
line producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19425/92A
Other languages
English (en)
Other versions
AU1942592A (en
Inventor
Jan Holmgren
Peter Lind
Leif Lindholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of AU1942592A publication Critical patent/AU1942592A/en
Assigned to PHARMACIA AB reassignment PHARMACIA AB Amend patent request/document other than specification (104) Assignors: KABI PHARMACIA AB
Application granted granted Critical
Publication of AU658198B2 publication Critical patent/AU658198B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU19425/92A 1991-07-03 1992-07-03 Tumour antigen specific antibody, its use and cell in line producing the antibody Ceased AU658198B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102074 1991-07-03
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (2)

Publication Number Publication Date
AU1942592A AU1942592A (en) 1993-01-07
AU658198B2 true AU658198B2 (en) 1995-04-06

Family

ID=20383243

Family Applications (2)

Application Number Title Priority Date Filing Date
AU19425/92A Ceased AU658198B2 (en) 1991-07-03 1992-07-03 Tumour antigen specific antibody, its use and cell in line producing the antibody
AU22920/92A Abandoned AU2292092A (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU22920/92A Abandoned AU2292092A (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line

Country Status (19)

Country Link
US (1) US5552293A (enExample)
EP (1) EP0521842B1 (enExample)
JP (1) JP3194020B2 (enExample)
KR (1) KR100246681B1 (enExample)
AT (1) ATE171193T1 (enExample)
AU (2) AU658198B2 (enExample)
CA (1) CA2073124C (enExample)
DE (1) DE69226990T2 (enExample)
DK (1) DK0521842T3 (enExample)
EE (1) EE03031B1 (enExample)
ES (1) ES2124250T3 (enExample)
FI (1) FI109207B (enExample)
HU (2) HU218084B (enExample)
IE (1) IE80841B1 (enExample)
IL (1) IL102390A (enExample)
NO (1) NO315472B1 (enExample)
NZ (1) NZ243435A (enExample)
SE (1) SE9102074D0 (enExample)
WO (2) WO1993001302A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
ATE200679T1 (de) * 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
ES2619313T3 (es) * 2001-03-15 2017-06-26 Precision Biologics, Inc. Terapia de anticuerpos monoclonales para el cáncer de páncreas
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
WO2004004639A2 (en) * 2002-07-02 2004-01-15 Smithkline Beecham Corporation A novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP3524611B1 (en) 2003-05-20 2020-12-30 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US9243062B2 (en) * 2005-08-11 2016-01-26 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
EP2399609B1 (en) 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
WO2010016527A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
RU2595424C2 (ru) 2009-06-03 2016-08-27 Иммьюноджен, Инк. Способы конъюгации
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
CN105209592A (zh) 2012-10-04 2015-12-30 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
WO2016081584A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
MX2018008383A (es) 2016-01-10 2019-05-30 Neotx Therapeutics Ltd Inmunoterapia contra el cáncer mediada por superantígeno mejorada por inmunopotenciador.
JP2019510741A (ja) 2016-02-05 2019-04-18 イミュノジェン・インコーポレーテッド 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
JP2022531978A (ja) 2019-05-15 2022-07-12 ネオティーエックス セラピューティクス リミテッド 癌治療
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
AU656906B2 (en) * 1990-07-20 1995-02-23 Active Biotech Ab Target specific antibody-superantigen conjugates and their preparation
AU657483B2 (en) * 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside

Also Published As

Publication number Publication date
HU211512A9 (en) 1995-11-28
FI935970A0 (fi) 1993-12-31
JPH05276987A (ja) 1993-10-26
IL102390A0 (en) 1993-01-14
ES2124250T3 (es) 1999-02-01
HU218084B (hu) 2000-05-28
HUT71193A (en) 1995-11-28
WO1993001303A1 (en) 1993-01-21
EE03031B1 (et) 1997-08-15
NO934777D0 (no) 1993-12-22
AU2292092A (en) 1993-02-11
ATE171193T1 (de) 1998-10-15
DK0521842T3 (da) 1999-06-14
IE80841B1 (en) 1999-03-24
EP0521842A2 (en) 1993-01-07
WO1993001302A1 (en) 1993-01-21
JP3194020B2 (ja) 2001-07-30
FI109207B (fi) 2002-06-14
CA2073124C (en) 2007-06-19
EP0521842A3 (enExample) 1994-01-26
IE922188A1 (en) 1993-01-13
DE69226990D1 (de) 1998-10-22
US5552293A (en) 1996-09-03
HU9400011D0 (en) 1994-05-30
EP0521842B1 (en) 1998-09-16
AU1942592A (en) 1993-01-07
KR100246681B1 (ko) 2000-04-01
IL102390A (en) 1996-01-19
SE9102074D0 (sv) 1991-07-03
NO934777L (no) 1994-02-11
NO315472B1 (no) 2003-09-08
FI935970L (fi) 1993-12-31
DE69226990T2 (de) 1999-03-25
NZ243435A (en) 1994-10-26
CA2073124A1 (en) 1993-01-04

Similar Documents

Publication Publication Date Title
AU658198B2 (en) Tumour antigen specific antibody, its use and cell in line producing the antibody
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
AU567693B2 (en) Human monoclonal antibodies against bacterial toxins
EP0212403A3 (en) Monoclonal antibodies to mucin-like human differentiation antigens
CA2192079A1 (en) Human Monoclonal Antibodies Specific to Cell Cycle Independent Glioma Surface Antigen
EP0218158A3 (en) Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
EP0190033A3 (en) Monoclonal antibody against a ras oncogene p21 related dodecapeptide
EP0299354A3 (en) Monoclonal antibodies against protein e7 of the human papilloma virus type 16, their production process and their use
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
AU2484488A (en) Method for the production of antigenic protein-hapten conjugates, and antibodies corresponding thereto
AU2687992A (en) Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof
CA2008735A1 (en) Human epidermal growth factor (egf) receptor sequences and egf competitive monoclonal antibodies
GR3024188T3 (en) Method of preparing 17-oxosteroids
IL37581A (en) A method for producing the methane oxidizing bacterial strain"m 102"and a method for synthesizing protein with it
AU8819391A (en) Antibody reactive to hamster immunoglobulins
PL271670A1 (en) Method of producing a line of lym-2 hybride cells and method of producing lym-2 antigens
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.